tetano
Editor, Senior Moderator
J Clin Lab Anal
. 2022 Apr 6;e24387.
doi: 10.1002/jcla.24387. Online ahead of print.
Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis
Adel Naimi[SUP] 1 [/SUP], Ilya Yashmi[SUP] 2 [/SUP], Reza Jebeleh[SUP] 2 [/SUP], Mohammad Imani Mofrad[SUP] 2 [/SUP], Shakiba Azimian Abhar[SUP] 2 [/SUP], Yasaman Jannesar[SUP] 2 [/SUP], Mohsen Heidary[SUP] 1 3 [/SUP], Reza Pakzad[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.
Material and methods: In this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated.
Results: In total, 53 studies with 2395 patients were included based on inclusion criteria. Most of these studies took place in Spain (14.81%), followed by the USA (11.11%), China (9.26%), and the UK (9.26%). More than half of COVID-19 patients with hematological malignancy were male (56.73%). Oxygen therapy played an important role in COVID-19 treatment. Moreover, anticoagulant therapies such as enoxaparin and heparin were two great assists for these patients. Fever (74.24%), cough (67.64%), and fatigue (53.19%) were the most reported clinical manifestations. In addition, hypertension and dyslipidemia were the most common comorbidities. The mortality rate due to COVID-19 in patients with hematological malignancies was 21.34%.
Conclusion: This study demonstrated that hematologic cancer patients were more susceptible to a severe COVID-19 than patients without blood cancer. Thus, the management of COVID-19 in these patients requires much more attention, and their screening should perform regularly.
Keywords: COVID-19; leukemia; lymphoma; myeloma; review.
. 2022 Apr 6;e24387.
doi: 10.1002/jcla.24387. Online ahead of print.
Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis
Adel Naimi[SUP] 1 [/SUP], Ilya Yashmi[SUP] 2 [/SUP], Reza Jebeleh[SUP] 2 [/SUP], Mohammad Imani Mofrad[SUP] 2 [/SUP], Shakiba Azimian Abhar[SUP] 2 [/SUP], Yasaman Jannesar[SUP] 2 [/SUP], Mohsen Heidary[SUP] 1 3 [/SUP], Reza Pakzad[SUP] 4 [/SUP]
Affiliations
- PMID: 35385130
- DOI: 10.1002/jcla.24387
Abstract
Introduction: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.
Material and methods: In this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated.
Results: In total, 53 studies with 2395 patients were included based on inclusion criteria. Most of these studies took place in Spain (14.81%), followed by the USA (11.11%), China (9.26%), and the UK (9.26%). More than half of COVID-19 patients with hematological malignancy were male (56.73%). Oxygen therapy played an important role in COVID-19 treatment. Moreover, anticoagulant therapies such as enoxaparin and heparin were two great assists for these patients. Fever (74.24%), cough (67.64%), and fatigue (53.19%) were the most reported clinical manifestations. In addition, hypertension and dyslipidemia were the most common comorbidities. The mortality rate due to COVID-19 in patients with hematological malignancies was 21.34%.
Conclusion: This study demonstrated that hematologic cancer patients were more susceptible to a severe COVID-19 than patients without blood cancer. Thus, the management of COVID-19 in these patients requires much more attention, and their screening should perform regularly.
Keywords: COVID-19; leukemia; lymphoma; myeloma; review.